Assuring that a stable cell line originates from a single progenitor cell is a fundamental component of the development of protein, cellular and gene therapies. However, monoclonality assurance is often a rate-limiting step in cell line development, leading to project delays and increased risk.
During the presentation, Adam Causer, Global Product Manager, Solentim Portfolio, Nova Biomedical, will provide an overview of an end-to-end workflow that not only achieves 99.99% probability of clonality but also digitalizes and automates the process of generating evidence of clonality for IND submissions.
Attendees will gain actionable insights into minimizing ghost well risk using gentle, automated single‑cell deposition, and an overview of how to achieve workflows capable of delivering greater than 99.99% Probability of Clonality when combined with high‑throughput whole‑well imaging — without sacrificing throughput or efficiency through the use of AI‑powered data management and analytics.
Read Also: Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026
